[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hong Kong Children's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":136},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,39,58,77,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100518745","phase-2-cd62l-depleted-donor-lymphocyte-infusion-with-t-cell-depleted-haploidentical-hematopoietic-stem-cell-transplantation-100518745",false,"NCT06034535","CD62L Depleted Donor Lymphocyte Infusion With T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Patient who requires allogeneic hematopoietic stem cell transplant, has no human leukocyte antigen (HLA)-matched sibling donor but has an HLA-haploidentical donor.\n* Adequate organ function to tolerate the conditioning chemotherapy and radiotherapy\n* Karnofsky or Lansky performance status score ≥50\n\nExclusion Criteria:\n\n* Pregnant or lactating woman\n* HIV infection\n* Patients for whom alternative treatment is deemed more appropriate by treating physician\n* Patients who are unlikely to benefit from haploidentical hematopoietic stem cell transplantation, e.g., terminal malignancy with multiorgan failure","ALL","18 Years",{"count":18,"type":19},23,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","In this clinical trial, the investigators aim to apply CD62L depleted donor lymphocyte infusion (DLI) together with in vitro T cell depleted haploidentical hematopoietic stem cell transplantation (HSCT) to treat patients with malignant or non-malignant disease in need of HSCT. The investigators shall evaluate the graft failure-free, graft-versus-host disease (GVHD)-free survival at one year, frequency of adverse events and post-transplant complications, and immunoreconstitution.",[25],"Hematopoietic Organs; Disorder","RECRUITING","2025-09-08",{"date":29,"type":30},"2025-09-15","ACTUAL",{"date":32,"type":30},"2023-09-01",{"date":34,"type":19},"2026-09",{"name":36,"class":37},"Hong Kong Children's Hospital","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":16,"enrollmentInfo":46,"targetDuration":4,"studyType":20,"phases":48,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":52,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":38},"100497241","phase-2-quadruple-immunotherapy-for-neuroblastoma-100497241","NCT05754684","Quadruple Immunotherapy for Neuroblastoma","Quadruple Immunotherapy for Paediatric Patients With Relapsed or Refractory Neuroblastoma","Inclusion Criteria:\n\n* relapsed or refractory neuroblastoma\n* Adequate organ function: creatinine clearance ≥40 ml\u002Fmin\u002F1.73m2, total bilirubin ≤3 times upper limit of normal and ALT ≤500 IU\u002FL, left ventricular shortening fraction ≥25%, and oxygen saturation ≥92% in room air\n* Karnofsky or Lansky performance status score ≥50\n* Has an appropriate HLA-haploidentical NK-cell donor available\n\nExclusion Criteria:\n\n* Pregnant or lactating woman\n* HIV infection\n* Patients for whom conventional treatment is deemed more appropriate\n* Patients who are unlikely to benefit, e.g., terminal malignancy with life expectancy \\\u003C1 month",{"count":47,"type":19},29,[22],"This is a single-arm clinical trial to evaluate the efficacy and safety of quadruple immunotherapy with natural killer (NK) cells, anti-GD2 antibody, cytokines (interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF)) and retinoid X receptor gamma (RXRg) agonist spironolactone for paediatric patients with relapsed or refractory neuroblastoma.",[51],"Neuroblastoma Recurrent",{"date":29,"type":30},{"date":54,"type":30},"2022-01-01",{"date":56,"type":19},"2025-12-31",{"name":36,"class":37},{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":16,"enrollmentInfo":64,"targetDuration":4,"studyType":20,"phases":65,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":38},"100521897","total-lymphoid-irradiation-as-conditioning-for-pediatric-haploidentical-hematopoietic-stem-cell-transplantation-100521897","NCT06075563","Total Lymphoid Irradiation as Conditioning for Pediatric Haploidentical Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Aged 0-18 years who requires allogeneic HSCT, has no human leukocyte antigen (HLA)-matched sibling donor but has an HLA-haploidentical donor.\n* Adequate organ function to tolerate the conditioning chemotherapy and radiotherapy\n* Karnofsky or Lansky performance status score ≥50\n\nExclusion Criteria:\n\n* Pregnant or lactating woman\n* HIV infection\n* Patients for whom alternative treatment is deemed more appropriate by treating physician\n* Patients who are unlikely to benefit from haploidentical hematopoietic stem cell transplantation, e.g., terminal malignancy with multiorgan failure",{"count":18,"type":19},[66],"NA","In this comparative study, the investigators aim to compare prospective pediatric patients who receive total lymphoid irradiation (TLI) using tomotherapy with age- and disease-matched controls who receive conventional total body irradiation (TBI) as part of conditioning for haploidentical hematopoietic stem cell transplantation (HSCT) for both malignant and non-malignant diseases. The investigators shall evaluate graft failure-free, graft-versus-host disease (GVHD)-free survival, overall survival, frequency of rejection, GVHD, relapse of malignancy, adverse effects and post-transplant immunoreconstitution.",[25],"2025-09-03",{"date":71,"type":30},"2025-09-10",{"date":73,"type":30},"2023-05-29",{"date":75,"type":19},"2026-12",{"name":36,"class":37},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":15,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":20,"phases":88,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":38},"100582712","cd-19-car-t-cell-for-pediatric-all-or-lymphoma-100582712","NCT06866873","CD-19 CAR-T Cell for Pediatric ALL or Lymphoma","Safety and Feasibility Study of CD19 Chimeric Antigen Receptor (CAR) T Cells in Children with Relapsed or Refractory CD19 Positive Acute Lymphoblastic Leukemia or Lymphoma","Inclusion Criteria:\n\n* Subjects must have relapsed or refractory ALL or lymphoma treated with at least two lines of therapy. Disease must have either progressed after the last regimen or presented failure to achieve partial or complete remission with the last regimen.\n* The patient's disease must be CD19 positive, either by immunohistochemistry or flow cytometry analysis on the last biopsy available.\n* Age 1-17 years.\n* Performance status: Subjects \\> 10 years of age: Karnofsky ≥ 50%; Subjects ≤ 10 years of age: Lansky scale ≥ 50%.\n* Normal organ function.\n\n  * Total bilirubin ≤ 3 times upper limit of normal\n  * AST (SGOT) ≤ 5 times upper limit of normal\n  * ALT (SGPT) ≤ 5 times upper limit of normal\n  * Serum Creatinine ≤ 2 times upper limit of normal\n  * Subjects must have the following hematologic function parameters: Hemoglobin (Hb) level \\> 8 g\u002FdL; Absolute Lymphocyte Count \\> 0.1x10\\^9\u002FL; Platelet \\> 50x10\\^9\u002FL\n* Prior therapy wash-out. At least 2 weeks or 5 half lives, whichever is shorter, must have elapsed since any prior systemic therapy at the time the subject is planned for leukapheresis.\n* Subjects' parent or legal guardian must have the ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Autologous transplant within 6 weeks of planned CAR T cell infusion.\n* Recipient of CAR-T cell therapy outside of this protocol.\n* Active central nervous system (CNS) or meningeal involvement by tumor.\n* History of additional active malignancy other than non-melanoma skin cancer, carcinoma in situ (e.g. cervix, bladder, breast).\n* Active human immunodeficiency virus (HIV) infection.\n* Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, pulmonary abnormalities or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant or breastfeeding women.\n* Evidence of myelodysplasia or cytogenetic abnormality indicative of myelodysplasia on any bone marrow biopsy prior to initiation of therapy.\n* Serologic status reflecting active hepatitis B or C infection.","1 Year","17 Years",{"count":87,"type":19},18,[66],"This study seeks to examine the efficacy and safety of the administration of autologous T cells that have been modified through the introduction of a chimeric antigen receptor (CAR) targeting the B cell surface antigen CD19 following administration of chemotherapy lymphodepletion regimen in children with relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoma. The overall goal of this study is to validate the safety profile of administration CD19-CAR T cells and describe the response rate in children with relapsed\u002Frefractory ALL or lymphoma.",[91,92],"Lymphoma, B-Cell","Acute Lymphoblastic Leukemia, Pediatric",[94,95],"CAR-T cell","Pediatric","2025-03-04",{"date":98,"type":30},"2025-03-10",{"date":100,"type":30},"2024-05-01",{"date":102,"type":19},"2037-12-31",{"name":36,"class":37},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":15,"minAge":111,"maxAge":16,"enrollmentInfo":112,"targetDuration":4,"studyType":20,"phases":114,"briefSummary":116,"conditions":117,"keywords":122,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":38},"100399018","phase-4-propofol-vs-sevo-for-paediatric-tumor-surgery-100399018","NCT04475705","Propofol vs Sevo for Paediatric Tumor Surgery","The Effects of Propofol Based Intravenous vs Sevoflurane Inhalation Anaesthesia on Inflammation and Circulating Tumor Cells in Paediatric Tumor Surgery - a Pilot Study","Inclusion Criteria:\n\n* patients coming for elective primary solid tumor resection for curative intent in Hong Kong Children's Hospital\n* AND patients \\> 5kg\n* AND patients within age limit\n\nExclusion Criteria:\n\n* Autoimmune \u002F Chronic inflammatory diseases e.g. Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA) etc.\n* Current Steroid therapy\n* Surgery for tumour removal in the past year\n* Allergy to Propofol\n* intraoperative use of nitrous oxide\n* Patient susceptible to Malignant Hyperthermia\n* Patients \u002F parents \u002F legal guardians showing preference in anaesthetic techniques during recruitment process","6 Months",{"count":113,"type":19},100,[115],"PHASE4","Background:\n\nRetrospective studies and meta-analyses have shown a reduction in 5-year survival following inhalational based compared to propofol based total intravenous (TIVA) anaesthesia for cancer surgery. To date there have been no prospective trials published which evaluate the effect of anaesthetic technique on circulating tumour cells (CTC), oxidative stress, and recurrence rate following cancer surgery. Children with cancer often require surgery for tumour excision as well as for other diagnostic and therapeutic procedures. To date there has been no prospective randomized controlled trial evaluating the optimal anaesthetic technique for surgery on children with cancer.\n\nAim:\n\nThis is a pilot study in paediatric patients who require surgery for tumour excision. The aim is to investigate the effect of sevoflurane inhalational versus propofol intravenous anaesthesia on expression of hypoxia-inducible factor 1 (HIF-1), circulating tumour cells, DNA damage and biomarkers of immunity and inflammation in patients before and after tumour surgery. The patients will be followed up for up to 5 years for tumour recurrence after surgery.\n\nMethod:\n\nThis will be a single-blinded randomized controlled trial. One hundred children undergoing tumour excision surgery at the Hong Kong Children's Hospital will be recruited and randomized to receive TIVA or inhalational anaesthesia. Baseline, intraoperative and postoperative blood will be taken for tests of immunity and inflammatory markers, DNA damage and circulating tumour cells. Patients would be followed up to 3 years for tumour recurrence and survival.",[118,119,120,121],"Solid Tumor","Carcinoma","Malignancy","Cancer",[123,124,125,126,127],"propofol","sevoflurane","cancer surgery","circulating tumor cells","paediatric","2022-03-14",{"date":130,"type":30},"2022-03-16",{"date":132,"type":30},"2021-01-11",{"date":134,"type":19},"2028-07",{"name":36,"class":37},""]